Published in FDA Law Weekly, December 16th, 2004
"We found a significant dose-related antinociceptive activity of ENT-103, which attenuated both phase I (acute pain) and phase II (tonic pain) of the formalin response when administered subcutaneously (under the skin)," said Sagen. "These results indicate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.